In Just One Dose

MIT's Tech Review reports on Alnylam's RNAi-based drug that, with one dose, lowers cholesterol by up to 60 percent in rodents and monkeys. The drug targets PCSK9, an enzyme that had been shown to affect LDL levels and people's risk of heart disease. The RNAi drug was bundled into lipid-based nanoparticles to be transported to the liver once injected. This drug, says the article, could be used in conjunction with statins to get LDL levels even lower.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.